past
decad
dramat
shift
occur
immunolog
theori
found
practic
applic
discoveri
design
novel
vaccin
adjuv
chang
think
driven
increas
appreci
activ
innat
immun
system
initi
amplifi
drive
antigenspecif
immun
respons
moreov
identif
discret
cell
type
specif
receptor
signal
pathway
involv
activ
innat
immun
provid
multitud
new
target
exploit
develop
novel
adjuv
immun
potenti
deliveri
system
combin
factor
increas
emphasi
field
vaccin
need
improv
safeti
exampl
subunit
vaccin
along
improv
efficaci
particularli
insidi
pathogen
exampl
human
immunodefici
viru
hiv
hepat
c
viru
hcv
recent
threat
bioterrorist
attack
ad
even
greater
sens
urgenc
effort
result
dramat
increas
effort
target
manipul
innat
immun
respons
improv
vaccin
adjuv
coincid
greater
mechanist
understand
might
optim
achiev
vaccin
consid
world
health
organ
costeffect
strategi
control
infecti
diseas
term
direct
effect
public
health
develop
present
avail
vaccin
second
introduct
clean
water
suppli
vaccin
work
manipul
bodi
immun
system
prepar
rapid
elimin
infecti
agent
andor
toxic
product
mechanist
perspect
vaccin
select
activ
expand
memori
b
cell
immun
system
pois
respond
rapidli
specif
subsequ
pathogen
exposur
sinc
edward
jenner
first
success
vaccin
smallpox
consid
birth
immunolog
scientif
disciplin
vaccin
design
discoveri
domin
pragmat
consider
one
use
work
regardless
understand
work
recent
year
howev
basic
immunolog
research
start
make
greater
contribut
vaccin
develop
process
mani
factor
drive
reinvigor
search
theoret
mechanist
underpin
vaccin
includ
need
develop
adjuv
design
histor
touch
alchemi
heart
due
relianc
complex
biolog
innat
immun
activ
howev
new
mechanist
understand
innat
immun
combin
new
adjuv
deliveri
platform
exploit
knowledg
led
signific
advanc
recent
although
mani
challeng
remain
field
move
rapidli
proper
tool
methodolog
place
use
tradit
drug
discoveri
engin
guid
develop
vaccin
adjuv
review
outlin
current
trend
immun
potenti
deliveri
system
adjuv
design
shape
vaccin
futur
vaccin
formul
local
vaccin
antigen
andor
immun
potenti
target
key
immun
cell
type
longliv
protect
immun
elicit
vaccin
mani
natur
occur
infect
mediat
expand
popul
previous
activ
b
cell
select
express
specif
receptor
antigen
given
pathogen
tlr
evolutionarili
conserv
famili
patternrecognit
receptor
detect
uniqu
microbi
product
allow
rapid
activ
innat
immun
respons
toward
cellular
humour
element
appropri
protect
particular
infecti
agent
although
overal
object
vaccin
activ
antigenspecif
immun
vaccin
optim
achiev
goal
without
effect
activ
pathogendetect
mechan
innat
immun
respons
vaccin
adjuv
broadli
defin
function
abil
enhanc
vivo
immunogen
antigenspecif
respons
antigen
coadminist
adjuv
repres
import
compon
success
vaccin
particularli
base
subunit
pathogen
includ
isol
fraction
kill
pathogen
recombin
antigen
howev
consequ
grow
appreci
innat
immun
mechan
detail
antigen
process
present
sophist
definit
adjuv
requir
therefor
begun
separ
tradit
novel
adjuv
two
main
categori
immun
potenti
deliveri
system
basi
domin
mechan
action
wherea
deliveri
system
mainli
function
local
vaccin
compon
target
vaccin
antigenpres
cell
apc
immun
potenti
directli
activ
cell
specif
receptor
exampl
tolllik
receptor
tlr
deliveri
system
use
promot
interact
antigen
immun
potenti
key
cell
innat
immun
system
immun
potenti
provid
inflammatori
context
necessari
optim
antigenspecif
immun
activ
activ
apc
amplifi
innat
immun
respons
fig
innat
defenc
strategi
design
detect
broad
conserv
pattern
differ
pathogen
organ
multicellular
host
nonantigenspecif
detect
strategi
mediat
divers
evolutionarili
conserv
famili
patternrecognit
receptor
prr
increas
number
prr
identifi
ten
recent
discov
member
tlr
famili
attract
interest
present
pathogenassoci
molecular
pattern
pamp
recogn
structur
chemic
divers
compound
share
common
featur
highli
conserv
pathogen
absent
multicellular
organ
broad
recognit
strategi
allow
innat
immun
system
respond
rapidli
infect
advanc
delay
activ
antigenspecif
immun
key
advantag
integr
system
pattern
recognit
antigenspecif
respons
immun
system
divid
respons
recogn
elimin
infecti
agent
fulfil
two
mutual
exclus
goal
primari
immun
respons
speed
specif
import
note
optim
immun
respons
requir
longterm
protect
immunityimmunolog
memori
repres
merger
two
compet
goal
vaccin
exploit
union
remark
success
fig
safer
better
defin
effect
vaccin
number
import
diseas
vaccin
present
exist
exampl
hiv
hcv
neisseria
meningitid
sever
acut
respiratori
syndrom
sar
furthermor
recent
breakthrough
immunolog
reveal
numer
new
target
mechan
innat
arm
immun
system
manipul
improv
adjuv
produc
better
vaccin
protect
immun
pathogen
exposur
achiev
integr
two
distinct
arm
immun
respons
innat
antigenspecif
also
call
adapt
respons
innat
respons
act
earli
infect
within
minut
detect
respond
broad
cue
invad
pathogen
contrast
adapt
respons
take
time
day
week
becom
effect
provid
fine
antigen
specif
requir
complet
elimin
pathogen
gener
immunolog
memori
antigenindepend
recognit
pathogen
innat
immun
system
lead
immedi
mobil
immun
effector
regulatori
mechan
provid
host
three
crucial
surviv
advantag
rapid
initi
immun
respons
innat
adapt
creation
inflammatori
costimulatori
context
antigen
recognit
establish
first
line
defenc
hold
pathogen
check
matur
adapt
respons
steer
adapt
immun
antigen
adjuv
deliveri
immun
potenti
figur
three
compon
optim
subunit
vaccin
well
known
subunit
vaccin
elicit
potent
durabl
antigenspecif
immun
combin
adjuv
vivo
adjuv
effect
divid
two
princip
compon
deliveri
immun
potenti
deliveri
system
local
antigen
target
appropri
cell
type
innat
immun
system
deliveri
also
optim
immun
potenti
target
immun
potenti
directli
activ
innat
immun
cell
provid
proinflammatori
context
antigen
recognit
antigen
provid
specif
pathogen
epitop
necessari
gener
longliv
immunolog
memori
three
compon
intrins
natur
occur
infect
wholecel
vaccin
wherea
must
combin
subunit
vaccin
formul
exampl
induc
full
activ
antigenspecif
cell
absenc
proinflammatori
cue
tcell
respons
shut
better
understand
antigen
present
apc
biolog
provid
opportun
futur
improv
vaccin
develop
select
sophist
immun
potenti
deliveri
system
develop
fig
among
emerg
target
immun
potenti
deliveri
system
b
cell
direct
adjuv
effect
b
cell
particularli
intrigu
seem
act
three
level
first
deliveri
system
especi
particul
one
facilit
order
repetit
array
bcell
epitop
result
effici
bcell
activ
antigen
receptor
second
although
b
cell
consid
part
antigenspecif
immun
system
also
express
prr
exampl
tlr
therefor
activ
pamp
immun
potenti
way
modifi
quantiti
qualiti
antibodi
respons
last
b
cell
also
act
apc
bcell
variou
cell
type
immun
system
capabl
present
antigen
cell
provid
crucial
bridg
innat
adapt
respons
among
dendrit
cell
dc
consid
profession
apc
highli
effici
special
function
dc
apc
constantli
sampl
environ
pinocytosi
andor
phagocytosi
use
prr
screen
infecti
agent
constitut
process
thought
provid
mechan
immun
system
mobil
innat
antigenspecif
defenc
infect
follow
vaccin
also
maintain
toler
nonrespons
autolog
benign
agent
dual
activationtoler
function
dc
mediat
capac
chang
context
antigen
present
commun
cell
natur
antigen
present
respond
pamp
synthet
immun
potenti
produc
proinflammatori
cytokin
express
costimulatori
molecul
immun
respons
first
encount
vaccin
infecti
agent
maxim
two
mutual
exclus
prioriti
host
defenc
speed
specif
equal
import
compet
goal
seen
merg
remark
effici
memori
respons
gener
rapid
specif
durabl
memori
respons
goal
vaccin
gener
immun
potenti
deliveri
system
target
innat
arm
wherea
vaccin
antigen
drive
pathogenspecif
respons
b
cell
b
arrow
indic
cytokin
network
crosstalk
regulatori
cell
innat
antigenspecif
immun
system
central
initi
amplif
specif
tand
bcell
respons
key
cytokin
amplifi
steer
effector
cell
gener
includ
type
ii
interferon
ifn
proinflammatori
mediat
exampl
tumournecrosi
factor
tnf
c
effector
memori
stage
elicit
cellmedi
humor
mechan
potent
specif
target
pathogen
andor
infect
cell
destruct
ab
antibodi
adcc
antibodydepend
cellmedi
cytotox
ctl
cytotox
lymphocyt
immpot
immun
potenti
mdcpdc
myeloidplasmacytoid
dendrit
cell
mono
monocyt
macrophag
nc
natur
cytotox
nk
natur
killer
cell
nkt
natur
killer
cell
phag
phagocytosi
pmn
polymorphonuclear
leukocyt
neutrophil
h
helper
cell
cellmedi
immun
h
helper
cell
humor
immun
infect
tradit
vaccin
immun
potenti
deliveri
system
use
improv
potenc
subunit
vaccin
need
low
cost
effect
safer
wholecel
vaccin
discoveri
tlr
famili
receptor
mani
pathogen
product
known
immunepotenti
activ
adjuv
shown
activ
innat
immun
via
tlr
increas
number
nontlr
prr
includ
rnadepend
kinas
pkr
ref
exampl
bacteri
lipopolysaccharid
lp
epitom
proinflammatori
agent
known
interact
specif
act
togeth
receptor
exampl
found
lpsrespons
cell
type
exampl
monocyt
macrophag
dc
b
cell
exampl
pathogen
product
correspond
tlrdepend
includ
triacyl
lipopeptid
lipid
peptid
protein
carbohydr
doublestrand
rna
poli
c
flagellin
diacyl
lipopeptid
cpg
dna
ten
tlr
famili
member
yet
natur
pathogenderiv
product
identifi
cooper
individu
tlr
prr
also
seem
gener
rule
natur
infect
tradit
wholecel
vaccin
moreov
tlr
seem
highli
promiscu
exampl
particip
respons
numer
divers
pathogen
product
intriguingli
also
implic
stressinduc
respons
pathogenand
hostderiv
heatshock
protein
observ
indic
play
gener
role
initiationamplif
earli
immun
respons
wherea
tlr
famili
member
perhap
prr
evolv
special
function
given
plethora
natur
product
capabl
activ
innat
immun
mechan
research
develop
effort
exploit
immun
potenti
adjuv
aggress
although
vivo
proof
concept
establish
use
mani
natur
pamp
adjuv
number
advanc
clinic
trial
trend
futur
indic
increas
relianc
synthet
analogu
due
mainli
lower
manufactur
regulatori
hurdl
associ
synthet
immun
potenti
highli
defin
standard
addit
synthet
platform
allow
ration
approach
optim
nextgener
compound
possess
greater
potenc
decreas
toxic
perspect
perhap
promis
adjuvantimmun
potenti
platform
recent
identifi
base
smallmolecul
approach
identif
imidizaquinolin
smallmolecul
immun
potenti
smip
indic
tradit
pharmaceuticalbas
druglik
molecul
exploit
vaccin
adjuv
inde
imidizaquinolin
activ
antigen
immun
potenti
enhanc
effici
antigen
present
cell
well
induc
product
cytokin
given
antibodi
respons
tradit
consid
correl
protect
vaccin
effort
select
target
b
cell
immun
potenti
deliveri
system
hold
great
promis
import
keep
mind
infecti
agent
licens
vaccin
particularli
live
attenu
kill
wholecel
product
contain
compon
necessari
activ
integr
immun
respons
pathogen
use
vaccin
possess
relev
antigen
particul
form
whole
cell
also
contain
mani
potent
immun
potenti
pamp
howev
trend
vaccin
develop
move
away
wholecel
product
toward
safer
betterdefin
subunit
vaccin
produc
highli
purifi
recombin
protein
unfortun
recombin
antigen
often
poorli
immunogen
lack
intrins
immunepotenti
activ
challeng
subunit
vaccin
develop
reintroduc
select
signal
activ
innat
immun
respons
suffici
mimic
natur
key
interact
driven
recognit
antigen
peptidemajor
histocompat
complex
mhc
dimer
cell
bear
tcell
receptor
tcr
high
affin
complex
howev
signal
alon
suffici
initi
amplif
specif
tcell
respons
costimulatori
signal
recognit
product
proinflammatori
cytokin
provid
infecti
context
full
activ
antigenspecif
cell
achiev
express
costimulatori
molecul
cytokin
apc
tightli
regul
induc
apc
encount
antigen
associ
pathogenassoci
molecular
pattern
perspect
adjuv
design
apc
highprior
target
deliveri
system
increas
antigen
uptak
present
also
target
immun
potenti
effici
apc
immun
potenti
induc
costimulatori
signal
cytokin
product
antigen
select
highli
specif
cell
lead
initi
amplif
antigenspecif
immun
ligand
pathogen
immun
system
evolv
combat
therefor
particul
normal
taken
effici
apc
function
mainli
deliv
associ
antigen
cell
main
hurdl
develop
new
improv
adjuv
safeti
vaccin
use
healthi
individu
need
induc
minim
advers
effect
prove
accept
use
although
mani
adjuv
extens
evalu
preclin
clinic
aluminium
salt
gener
call
alum
success
licens
use
vaccin
adjuv
north
america
howev
altern
particul
deliveri
system
microemuls
ref
success
introduc
onto
market
europ
use
conjunct
influenza
vaccin
fluad
chiron
seem
function
adjuv
mainli
promot
uptak
coadminist
vaccin
antigen
apc
although
shown
safe
efficaci
wide
rang
clinic
trial
earli
clinic
develop
yield
number
import
lesson
origin
microemuls
use
deliveri
system
potent
adjuv
activ
molecul
lipid
muramyl
tripeptid
mtppe
novel
synthet
deriv
mycobacteri
cell
wall
howev
combin
prove
reactogen
routin
clinic
use
although
alon
welltoler
compar
immunogen
combin
consequ
alon
use
subsequ
prove
suffici
potent
safe
allow
success
product
develop
clinic
experi
microemuls
serv
highlight
need
care
select
immun
potenti
includ
vaccin
overal
although
normal
potent
adjuv
alum
like
alum
expect
appropri
use
vaccin
work
well
varieti
antigen
enhanc
antibodi
tcell
prolif
respons
howev
unabl
induc
potent
tcell
respons
h
type
defin
product
cytokin
might
requir
provid
protect
immun
intracellular
pathogen
clear
addit
adjuv
deliveri
approach
need
vaccin
recent
past
focus
altern
particul
deliveri
system
vaccin
compris
biodegrad
microparticl
prepar
polym
poli
lactid
coglycolid
plg
plg
polym
alreadi
use
varieti
biomed
purpos
includ
prepar
controlledreleas
deliveri
system
therapeut
protein
human
growth
hormon
excel
choic
vaccin
deliveri
system
addit
microparticl
appropri
size
shown
taken
apc
vivo
migrat
tcell
area
local
lymph
node
differenti
matur
dc
initi
work
focus
use
microparticl
control
releas
trap
antigen
object
make
singledos
vaccin
shown
enhanc
antigenspecif
respons
mous
model
therefor
potenti
develop
adjuv
human
smipbas
platform
adjuv
design
discoveri
hold
signific
potenti
futur
vaccin
develop
numer
advantag
realiz
throughout
vaccin
r
pipelin
smip
rather
natur
synthet
immun
potenti
chosen
optim
develop
adjuv
discoveri
effort
incred
divers
scaffold
gener
combinatori
chemistri
abil
target
except
select
innat
immun
mechan
tri
test
drug
discoveri
engin
highthroughput
screen
hittolead
optim
appli
vaccin
adjuv
later
develop
manufactur
smipbas
adjuv
provid
low
cost
highli
pure
standard
altern
exist
candid
immun
potenti
given
advantag
likelihood
divers
famili
smip
discov
seem
imidizaquinolin
agonist
repres
first
long
line
futur
smallmoleculebas
vaccin
adjuv
candid
although
term
adjuv
deliveri
system
often
use
interchang
relat
vaccin
clear
distinct
often
made
respect
role
clearli
differenti
particularli
deliveri
system
use
vaccin
adjuv
includ
list
vaccin
adjuv
number
particul
deliveri
system
exampl
emuls
liposom
iscom
viruslik
particl
microparticl
whose
princip
mode
action
promot
uptak
antigen
key
apc
respons
induct
immun
respons
howev
potenc
deliveri
system
significantli
improv
addit
vaccin
adjuv
immun
potenti
adjuv
includ
deliveri
system
focu
effect
onto
apc
minim
effect
nonimmun
cell
henc
deliveri
system
improv
therapeut
ratio
adjuv
geograph
concept
immun
reactiv
antigen
reach
local
lymph
node
induc
respons
accept
role
import
deliveri
system
becom
clear
deliveri
system
serv
maxim
concentr
antigen
local
lymph
node
either
directli
promot
antigen
uptak
lymphat
promot
antigen
uptak
motil
apc
migrat
lymph
node
role
vaccin
deliveri
system
enhanc
amount
antigen
reach
cell
tissu
respons
immun
respons
induct
particul
vaccin
deliveri
system
exampl
emuls
microparticl
iscom
liposom
virosom
viruslik
particl
compar
dimens
microparticl
particul
carrier
system
micron
size
rang
normal
prepar
synthet
polym
use
deliveri
system
drug
vaccin
usual
trap
within
particl
oilinwat
microemuls
adjuv
approv
europ
use
combin
influenza
vaccin
elderli
fluad
poli
lactid
coglycolid
plg
biodegrad
biocompat
synthet
polym
use
prepar
number
success
market
drug
deliveri
system
deliv
adsorb
dna
dc
wherea
nake
dna
unabl
transfect
dc
similar
cation
microparticl
also
use
deliveri
system
adsorb
adjuv
includ
cpg
dna
wherea
anion
microparticl
use
adsorb
protein
vaccin
potenti
broad
rang
particul
vaccin
deliveri
system
improv
potenc
new
gener
vaccin
recent
review
detail
although
major
vaccin
tradit
administ
inject
mucos
administr
vaccin
offer
number
import
advantag
includ
easier
administr
reduc
advers
effect
potenti
frequent
boost
addit
mucos
immun
induc
local
immun
site
pathogen
often
establish
infect
oral
immun
would
particularli
advantag
isol
commun
access
health
care
profession
problemat
moreov
mucos
immun
would
avoid
problem
infect
due
reus
needl
common
develop
world
howev
difficulti
develop
mucos
particularli
oral
vaccin
use
nonliv
approach
underestim
protein
peptid
polysaccharid
dna
immunogen
extrem
labil
extens
degrad
damag
passag
gut
adequ
protect
intranas
immun
attract
approach
owe
absenc
acid
secret
enzym
nasal
caviti
also
eas
access
nasal
caviti
offer
simpl
commerci
avail
devic
nevertheless
potent
adjuv
deliveri
system
requir
facilit
develop
effect
mucos
vaccin
potent
mucos
adjuv
avail
bacteri
toxin
secret
escherichia
coli
vibrio
cholera
call
heatlabil
enterotoxin
lt
fig
cholera
toxin
ct
respect
howev
molecul
respons
travel
diarrhoea
cholera
respect
nativ
molecul
clearli
appropri
mucos
administr
human
therefor
molecul
manipul
reduc
toxic
retain
adjuv
activ
fig
one
particular
mutant
lt
recent
shown
safe
human
clinic
trial
involv
intranas
administr
follow
extens
preclin
toxicolog
test
previou
studi
show
potenc
intranas
administr
could
enhanc
coadministr
bioadhes
deliveri
system
small
larg
anim
model
bioadhes
deliveri
system
design
retain
vaccin
formul
nasal
caviti
extend
period
promot
interact
antigen
adjuv
mucos
epithelium
recent
data
indic
might
prove
suffici
potent
allow
mucos
administr
paediatr
combin
vaccin
howev
problem
aros
consequ
degrad
antigen
follow
microencapsul
releas
plg
microparticl
therefor
adopt
novel
approach
adsorb
antigen
onto
surfac
microparticl
avoid
expos
damag
condit
encapsul
releas
adsorpt
enhanc
use
charg
surfact
microparticl
prepar
promot
antigen
interact
surfac
particl
consequ
microparticl
design
perform
deliveri
system
promot
uptak
antigen
apc
therebi
result
induct
potent
antibodi
tcell
respons
mice
nonhuman
primat
addit
adsorpt
antigen
microparticl
also
serv
multimer
antigen
facilit
direct
recognit
bcell
antigen
receptor
approach
adsorb
antigen
onto
charg
microparticl
proven
suffici
flexibl
allow
success
deliveri
dna
vaccin
adsorb
onto
surfac
cation
microparticl
fig
use
cation
microparticl
deliveri
system
dna
vaccin
result
significantli
enhanc
immun
respons
comparison
immun
use
nake
dna
mice
nonhuman
primat
mechanist
studi
show
cation
plg
microparticl
abl
heatlabil
enterotoxin
lt
bacteri
toxin
secret
escherichia
coli
potent
immunostimulatori
appli
mucos
surfac
also
act
adjuv
coadminist
antigen
howev
molecul
also
caus
agent
travel
diarrhoea
vaccin
administ
infant
toddler
would
prefer
could
administ
without
use
needl
addit
needl
phobia
signific
problem
make
difficult
convinc
adult
receiv
vaccin
problem
might
becom
particularli
acut
futur
prove
necessari
immun
larg
number
individu
respons
pandem
strain
influenza
threat
bioterror
attack
problem
relat
vaccin
needl
even
greater
develop
world
reus
needl
often
result
transmiss
bloodborn
pathogen
hiv
hcv
although
problem
partli
remedi
develop
singleus
autodispos
syring
needlebas
inject
still
repres
infecti
threat
must
dispos
care
one
approach
obviat
problem
associ
vaccin
administ
needl
involv
number
devic
design
deliv
vaccin
skin
without
use
needl
multipleus
jet
injector
devic
deliv
liquid
vaccin
skin
wide
use
mass
immun
campaign
throughout
howev
devic
becam
discredit
becam
appar
capabl
transmit
bloodborn
pathogen
hepat
b
recent
singledos
jet
injector
devic
develop
capabl
deliv
liquid
dri
powder
vaccin
skin
use
high
pressur
addit
springpow
liquid
inject
devic
avail
also
evalu
clinic
howev
none
devic
yet
attain
broad
accept
medic
commun
cost
make
difficult
imposs
implement
develop
world
highpressureliquid
needlefre
devic
also
use
deliveri
dna
vaccin
clinic
trial
new
needlefre
devic
design
deliv
gold
bead
coat
dna
skin
gene
gun
altern
needlefre
approach
vaccin
deliveri
could
perhap
describ
accur
needlelit
involv
use
microproject
array
design
painlessli
disrupt
outer
layer
skin
allow
vaccin
access
epidermi
associ
langerhan
cell
perhap
attract
needlefre
approach
vaccin
deliveri
explor
present
involv
transcutan
immun
topic
applic
vaccin
patch
approach
recent
provid
promis
observ
clinic
trial
addit
abil
number
differ
adjuv
function
follow
topic
applic
vaccin
encourag
abil
topic
appli
immunostimulatori
patch
enhanc
immunogen
local
inject
vaccin
addit
mucos
immun
approach
discuss
clearli
fall
needlefre
categori
vaccin
might
also
administ
mucos
via
aerosol
includ
measl
vaccin
howev
avail
devic
need
made
robust
reliabl
broadli
accept
vaccin
administr
although
oral
deliveri
nonliv
vaccin
remain
extrem
challeng
even
potent
adjuv
success
achiev
small
anim
model
nontox
lt
mutant
nevertheless
requir
develop
optim
deliveri
system
success
oral
vaccin
produc
commerci
varieti
microparticlebas
deliveri
system
design
protect
antigen
degrad
gut
promot
interact
epithelium
taken
mucosalassoci
lymphoid
tissu
offer
signific
promis
import
compon
oral
vaccin
deliveri
system
recent
success
achiev
human
clinic
trial
vaccin
trap
plg
microparticl
approach
like
requir
signific
improv
allow
success
commerci
develop
broadest
sens
concept
vaccin
deliveri
system
expand
includ
rang
devic
physic
deliveri
system
design
allow
immun
use
novel
noninvas
rout
needlefre
vaccin
attract
number
reason
develop
world
concern
number
transcutan
immun
involv
topic
applic
vaccin
usual
special
design
patch
mediat
effect
immun
without
penetr
protect
layer
skin
devic
needl
subunit
compris
globular
structur
enzymat
activ
mediat
adpribosyl
result
perman
activ
adenyl
cyclas
abnorm
intracellular
accumul
camp
massiv
fluid
loss
result
diarrhoea
subunit
link
b
oligom
long
helic
subunit
must
proteolyt
cleav
addit
disulphid
reduc
releas
activ
subunit
adpribosyltransferas
activ
subunit
enhanc
interact
intracellular
adpribosyl
factor
arf
variou
group
attempt
gener
potent
safe
mucos
adjuv
lt
varieti
genet
manipul
chiron
scientist
focus
modifi
elimin
enzymat
activ
lt
adpribosyl
singl
aminoacid
substitut
activ
site
altern
approach
pursu
other
modifi
abil
subunit
proteolyt
cleav
trypsin
allow
vaccin
use
treat
chronic
infecti
diseas
autoimmun
cancer
howev
potenc
adjuv
need
care
balanc
potenti
overactiv
immun
system
damag
consequ
regard
vaccin
adjuv
deliveri
system
might
role
play
limit
system
distribut
adjuv
follow
administr
moreov
main
role
vaccin
deliveri
system
ensur
antigen
adjuv
interact
optim
appropri
immunocompet
cell
induc
desir
respons
nevertheless
adjuv
capabl
initi
potent
inflammatori
respons
limit
abil
act
broad
rang
cell
could
prove
import
focus
effect
key
immun
cell
overal
clear
pharmaceut
scientist
uniqu
import
role
play
develop
optim
vaccin
adjuv
deliveri
system
system
mucos
administr
enter
excit
dynam
time
vaccin
research
principl
govern
success
induct
potent
protect
immun
respons
becom
better
understood
forefront
work
discoveri
relat
presenc
receptor
innat
immun
cell
recogn
characterist
pattern
compon
present
pathogen
recognit
import
activ
innat
immun
system
eventu
induct
antigenspecif
immun
fire
enthusiasm
identifi
pathogenbas
ligand
receptor
potenti
newgener
adjuv
use
combin
recombin
protein
signific
amount
work
underway
area
like
lead
develop
whole
new
class
vaccin
adjuv
abl
control
manipul
immun
respons
varieti
way
like
adjuv
could
prove
suffici
potent
vitro
toxic
adren
cell
shown
heatlabil
enterotoxin
lt
wild
type
ltwt
mutant
gener
chiron
modif
enzymat
activ
site
subunit
altern
mutant
modifi
abil
enzymat
cleav
activ
trypsin
enzym
activ
subunit
show
toxic
cell
wherea
residu
enzym
activ
ltwt
show
residu
toxic
less
toxic
ltwt
contrast
show
margin
reduct
toxic
similar
result
obtain
vivo
toxic
standard
rabbit
ileal
loop
model
show
signific
fluid
accumul
ltwt
contrast
show
fluid
accumul
even
highest
dose
test
mg
wherea
show
reduc
fluid
accumul
requir
higher
dose
trigger
effect
show
high
level
fluid
accumul
even
low
dose
similar
ltwt
probabl
altern
enzym
present
cleav
molecul
addit
trypsin
detail
experiment
methodolog
studi
see
ref
